Relay Therapeutics, Inc. (RLAY)
|Net Income (ttm)||n/a|
|Trading Day||January 15|
|Day's Range||42.25 - 45.92|
|52-Week Range||32.81 - 54.03|
CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY) is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12,...
Relay Therapeutics Announces a Worldwide License and Collaboration Agreement with Genentech for RLY-1971
Collaboration brings together clinical stage SHP2 and KRAS G12C inhibitors
CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging u...
Relay Therapeutics: Heavily Backed Biotech Brains Trust Looks A Long-Term Buy
Relay Therapeutics Announces Dosing of First Patient in First-in-Human Clinical Trial of RLY-4008, a Highly Selective FGFR2 Inhibitor
CAMBRIDGE, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveragin...
CAMBRIDGE, Mass., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging...
Relay Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
CAMBRIDGE, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by leveraging...
TAIPEI, Taiwan--(BUSINESS WIRE)--Oak Stone Limited says SoftBank-backed Relay Therapeutics has soared 75% in its trading debut, expanding its IPO to raise $400 million.
IPOS to watch: Relay Therapeutics and Trean Insurance Group
Yahoo Finance's Jared Blikre breaks down IPOs Relay Therapeutics and Trean Insurance Group.
Relay Therapeutics's stock sprints out of the gate, after upsized IPO priced above recently raised expectations
Shares of Relay Therapeutics Inc. RLAY, +67.10% sprinted out of the gate Thursday, after the clinical-stage oncology company's upsized initial public offering priced above the expected range.
Relay Therapeutics raised $400 million with an initial public offering that priced late Wednesday and surpassed expectations. The Relay Therapeutics IPO will begin trading Thursday morning.
Relay Therapeutics operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor of the protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 (SHP2) that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor of f... [Read more...]
|IPO Date |
Jul 16, 2020
|Stock Exchange |
|Ticker Symbol |
According to 6 analysts, the average rating for RLAY stock is "Buy." The 12-month stock price forecast is 55.60, which is an increase of 23.97% from the latest price.